Interestingly, a strong rationale for developing survivin-based anti-cancer vaccines emerged when the above findings were confirmed in mouse models of lymphoma and pancreatic cancer by the identification of cytotoxic CD8+ T lymphocytes that were responsive to some of survivin’s epitopes. This evidence concerns the gene BIRC5 and cancer.